COMMUNIQUÉS West-GlobeNewswire

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
27/04/2026
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting [...]
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
27/04/2026
Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. ( [...]
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
27/04/2026
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a [...]
Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting
27/04/2026
- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma - SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology [...]
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
27/04/2026
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS [...]
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
27/04/2026
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6) Persistence observed through [...]
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
27/04/2026
MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and [...]
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
27/04/2026
MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
InspireMD to Announce First Quarter 2026 Financial Results
27/04/2026
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter [...]
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today [...]
The Joint Corp. Signs Asset Purchase Agreement to Sell 45 Corporate-Owned Clinics in Southern California
27/04/2026
- Effectively Positions The Joint as a Pure-play Franchisor - SCOTTSDALE, Ariz., April 27, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) (the “Company”), the nation's largest franchisor of chiropractic care [...]
Arbor Biotechnologies to Present Expansion of CNS Editing Platform Capabilities at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
27/04/2026
- Oral presentation highlights novel compact RT editor demonstrating first preclinical in vivo proof of concept for precise gene editing in the CNS delivered via a single AAV - Poster presentations showcase deepening [...]
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
27/04/2026
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for [...]
TOMI Environmental Positioned for Accelerated Growth as Robotaxi Market Rapidly Expands
27/04/2026
TOMI Leverages Proprietary SteraMist iHP Technology to Scale Global Fleet Disinfection FREDERICK, Md., April 27, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in [...]
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
27/04/2026
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% [...]
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
27/04/2026
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and [...]
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving [...]
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five [...]
Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
27/04/2026
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]

Pages